Experimental studies have shown that FGF21 can mitigate free fatty acid-induced nephritis in mice, reduce monosodium glutamate (MSG)-induced hepatic steatosis in obese mice, alleviate high-fat diet (HFD)-induced NAFLD, and attenuate lipopolysaccharide (LPS)-induced sepsis-associated inflammation (33–36). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.